BioCopy raises CHF 9M to push bispecific antibodies toward cancer trials
What's the deal? Basel-based biotech BioCopy has raised CHF 9 million as part of its Series A round to advance a pipeline of T-cell receptor mimetic (TCRm) bispecific antibodies for cancer immunotherapy. The financing will fund IND-enabling studies for the company's lead candidate, with a Phase 1 trial targeted for late 2027.
BioCopy is a Swiss-German company with headquarters in Basel and an R&D facility in Emmendingen, Germany. It combines proprietary ultra-high-throughput screening, artificial intelligence, and wet-lab experimental feedback to develop biotherapeutics.
Why now? TCRm bispecific antibodies are an emerging approach in oncology. By simultaneously engaging peptide human leukocyte antigen (pHLA) complexes on tumour cells — which present intracellular cancer antigens inaccessible to conventional antibodies — and redirecting cytotoxic T cells, BioCopy's candidates aim to address a broader range of cancer indications than existing therapies.
The company's portfolio includes five bispecific TCRm development candidates, each designed to target distinct tumour-associated pHLA epitopes. The fresh capital positions BioCopy to move its most advanced programme through the preclinical gauntlet and into the clinic.
What could go wrong? Bispecific antibodies targeting pHLA complexes face steep technical hurdles. Achieving sufficient specificity to avoid off-target toxicity while maintaining potent anti-tumour activity remains a core challenge. A Phase 1 timeline of late 2027 also leaves room for regulatory or manufacturing delays that could push first-in-human dosing further out.
CHF 9 million is a modest war chest for a company attempting to bring a novel biologic into clinical trials. BioCopy will likely need additional capital before or during Phase 1.
The signal: BioCopy's CHF 9 million raise comes as the company sits at what Dealroom classifies as the "breakout" growth stage — a point where many biotech startups struggle to bridge the gap between preclinical promise and clinical reality. The round underscores a broader trend of early-stage capital flowing toward differentiated immuno-oncology platforms that combine computational and wet-lab approaches, even as investors remain cautious about the long timelines and capital intensity inherent in novel biologics development.
Read more: startupticker.ch
